EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

A critical review of management of allogeneic transplant‐eligible adults with Ph+ acute lymphoblastic leukaemia

Naranie Shanmuganathan iD, Andrew Grigg

British Journal of Haematology · 2026-01 · 208 (1) · 39-53

DOI: 10.1111/bjh.19682 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Haematology, online erschienen am 17.09.2024. Verfasst von Naranie Shanmuganathan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hematopoietic Stem Cell Transplantation, Philadelphia Chromosome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute lymphoblastic leukaemia (ALL) in 20%–30% of adult patients contains the Philadelphia (Ph+) chromosome. Historically, Ph+ ALL denoted a markedly inferior outcome and long‐term survival in the absence of an allograft was uncommon. However, the advent of targeted therapy directed against the BCR::ABL1 fusion protein with various tyrosine kinase inhibitors (TKIs) has markedly improved the prognosis, resulting in a number of treatment controversies in allograft‐eligible patients. Which is the best TKI to use in induction? What is the clinical relevance of the subdivision of Ph+ ALL into multilineage vs lymphoid types? Do all patients in first morphological complete remission (CR1) after induction and consolidation with chemotherapy/TKI require an allograft? If not, what risk factors predict a poor outcome without an allograft? Can chemotherapy‐free approaches, such as blinatumomab in conjunction with more potent TKIs, obviate the need for an allograft in high‐risk patients? What is the best strategy to deal with persistent or emerging minimal residual disease both pre‐ and post‐transplant? Is maintenance TKI indicated in all patients post allograft? Can salvage therapy and a subsequent allograft cure patients who relapse after not being transplanted in CR1? This manuscript reviews the latest data influencing contemporary management and discusses these controversies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaHematopoietic Stem Cell TransplantationPhiladelphia ChromosomeHumansAdultTransplantation, HomologousProtein Kinase InhibitorsNeoplasm, ResidualAllograftsFusion Proteins, bcr-abl

Stichwörter der Autor:innen

BCR::ABL1MRDacute leukaemiastem cell transplantation

Substanzen

Protein Kinase InhibitorsFusion Proteins, bcr-abl

Autor:innen und Institutionen

  • Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, South Australia, Australia.
  • Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, South Australia, Australia.
  • Department of Clinical Haematology, Austin Hospital, Heidelberg, Victoria, Australia.

ORCID-Profile: Naranie Shanmuganathan

Zitieren

APA

Shanmuganathan, N., & Grigg, A. (2026). A critical review of management of allogeneic transplant‐eligible adults with Ph+ acute lymphoblastic leukaemia. British Journal of Haematology, 208(1), 39-53. https://doi.org/10.1111/bjh.19682

Vancouver

Shanmuganathan N, Grigg A. A critical review of management of allogeneic transplant‐eligible adults with Ph+ acute lymphoblastic leukaemia. British Journal of Haematology. 2026;208(1):39-53. doi:10.1111/bjh.19682

BibTeX
@article{Shanmuganathan2026,
  author = {Shanmuganathan, Naranie and Grigg, Andrew},
  title = {A critical review of management of allogeneic transplant‐eligible adults with Ph+ acute lymphoblastic leukaemia},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {208},
  number = {1},
  pages = {39--53},
  doi = {10.1111/bjh.19682}
}
Kostenlos starten →